Mavacamten Safety and Real-World Data Emerging at ACC.26, With Matthew Martinez, MD

13 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Real-world evidence continues to refine the clinical profile of mavacamten in obstructive hypertrophic cardiomyopathy (HCM), with new data from both the MARVEL-HCM cohort and a large US Risk Evaluation and Mitigation Strategy (REMS) registry analysis reinforcing its effectiveness and safety in routine practice.
In an interview with HCPLive, Matthew Martinez, MD, associate professor of medicine, director of sports cardiology, and director of the Hypertrophic Cardiomyopathy program at Morristown Medical Center/Atlantic Health System, discussed the emerging data from the MARVEL-HCM trial, presented at the American College of Cardiology (ACC) Scientific Sessions 2026 in New Orleans, Louisiana.

“I think the real-world data is going to be critical,” Martinez said. “You’re already seeing the ability to be a little more granular with some of the real-world data, such as MARVEL and COLLIGO, because it allows us to ask other questions that may not have been specifically addressed during the clinical trials that led to mavacamten’s approval. All of these real-world studies allow us just a glimpse into what’s happening outside of large academic centers.”

Read the full article here: https://www.hcplive.com/view/mavacamten-safety-and-real-world-data-emerging-at-acc-26-with-matthew-martinez-md

Key Timestamps
00:00:01 Intro
00:00:08 Safety data and confidence in use
00:01:09 Most critical aspects of safety data
00:02:37 Safety data and incorporation thresholds
00:03:35 Safety data and treatment expectations
00:05:25 Looking ahead at real-world data

#cardiology #acc26
Categoria
Cardiology
Commenta per primo questo video.

Prossimo